J&J/Firefly, Roche/Nurix each strike degrader deals: Deals Report

J&J’s $1 billion deal for privately held Firefly is the biggest commitment yet by a pharma buyer in the emerging field of degrader-antibody conjugates (DACs), following a pair of recent agreements.

The deal had the second largest upfront payment of the past few days, topped only by the takeout of  Vega Therapeutics Inc. by  Incyte Corp. (NASDAQ:INCY). It was also one of two degrader deals in the spotlight Monday...